APA

Inomata M., Hayashi R., Tanaka H., Shimokawa K., Tokui K., Taka C., Okazawa S., Kambara K., Ichikawa T., Yamada T., Miwa T., Kashii T., Matsui S. & Tobe K. (2016). Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. : Molecular and clinical oncology.

Chicago

Inomata Minehiko, Hayashi Ryuji, Tanaka Hiroaki, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Ichikawa Tomomi, Yamada Toru, Miwa Toshiro, Kashii Tatsuhiko, Matsui Shoko and Tobe Kazuyuki. 2016. Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. : Molecular and clinical oncology.

Harvard

Inomata M., Hayashi R., Tanaka H., Shimokawa K., Tokui K., Taka C., Okazawa S., Kambara K., Ichikawa T., Yamada T., Miwa T., Kashii T., Matsui S. and Tobe K. (2016). Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. : Molecular and clinical oncology.

MLA

Inomata Minehiko, Hayashi Ryuji, Tanaka Hiroaki, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Ichikawa Tomomi, Yamada Toru, Miwa Toshiro, Kashii Tatsuhiko, Matsui Shoko and Tobe Kazuyuki. Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. : Molecular and clinical oncology. 2016.